Innovative biopharmaceutical companies a significant risk of dynamic analysis of continuous innovation and response measures
|School||Kunming University of Science and Technology|
|Course||Technology Economics and Management|
|Keywords||innovative enterprises sustainable innovation innovative biopharmaceutical enterprise major risk|
With the technology advances, the competition grows rapidly, the innovation become the significant factor to the country and enterprises. The 17th Party Congress report clearly pointed out that improves the capability of independent innovation and building innovation-oriented country. After that, the construction of innovative enterprises become rapidly. The essence of Innovative enterprises is sustainable innovation. To build Innovative enterprises are both the requirements of building an innovative country and enhance their core competitiveness of enterprise internal needs. Innovative biopharmaceutical enterprises are essential power to building an innovative country, and strategic transition period is a significant risk of sensitive period. In this period, the significant risk without effective control will bring significant impact on the sustainable innovation, even lead to the termination of sustainable innovation. Therefore, the analysis of the major risk during the process of sustainable innovation in the innovative enterprise is necessary.At present, domestic and foreign research on innovative enterprise risk management is normally focused on technological innovation risk management, product innovation risk management. Innovative enterprise risk management research literature, particularly innovative risk management research of innovative bio-pharmaceutical enterprises is so poor that could not meet the needs of innovative business practices. Innovative bio-pharmaceutical enterprise’ innovate major risk management research is needed for deepening and perfecting the theory of innovative enterprises. Also it is required for guiding the smooth implementation of innovative business. Based on these, refer to innovation, sustainable innovation, innovative enterprises, risk management and other theoretical results, deep enterprise research was did, a combination of qualitative and quantitative analysis and a combination of theoretical and case analysis method were used in this paper. Therefore, the mainly contents are as the following aspects:1. On the basis of innovation theory, enterprise sustainable innovation, risk management and bio-pharmaceutical enterprises, the paper put forward the innovative concept of bio-pharmaceutical enterprises, and reveals the dynamic changes of major risks during the process of enterprise sustainable innovation;2.Divided sustainable innovation process of innovative biopharmaceutical enterprise into three stages, and identify some major innovative risk factors during the sustainable innovation process, also divided these risk factors into two main factors—categories-internal and external risk, which is the basis of risk assessment;3.Build the theoretical framework system of sustainable innovation process in innovative biopharmaceutical enterprise; establish a scientific, systematic and effective evaluation, and take a close degree method which based on fuzzy analysis;4. On the basis of fuzzy close degree, the paper completed the empirical analysis of A innovative pharmaceutical enterprise. It can be seen that although this enterprise is recognized as a fine business in this field, but there still are risk which may be expanded. This paper proposed a corresponding risk response measures and recommendations and also verified the feasibility of the theory.This paper has supported by the National Natural Science Foundation of China. The title of the project is "the research on major risk of enterprise’s sustainable innovation process dynamical identification, assessment and management mechanism", and the project number is 70862002.